On March, 14 WallStreet expected Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s earnings report, Zacks reports. Analysts predict 600.00 % diference or $-0.10 from the $0.02 EPS from 2018. Last quarter $-0.15 EPS was reported. Analysts predicts -33.33 % EPS growth this quarter. BCLI reached $4.0285 during the last trading session after $0.0215 change.Brainstorm Cell Therapeutics Inc. has 83,724 shares volume, 23.50% up from normal. BCLI is downtrending and has moved 25.37% since February 26, 2018. BCLI underperformed by 25.37% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others.The firm is valued at $83.42 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.Last it reported negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

For more Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news released briefly go to: Seekingalpha.com, Globenewswire.com, Seekingalpha.com, Prnewswire.com or Seekingalpha.com. The titles are as follows: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” released on May 14, 2018, “BrainStorm Appoints Arturo Araya as Chief Commercial Officer – GlobeNewswire” on September 04, 2018, “Brainstorm Cell Therapeutics (BCLI) Presents At 10th Annual Biotech Showcase 2018 – Slideshow – Seeking Alpha” with a publish date: January 10, 2018, “BrainStorm to Host Call Following President Trump’s Citing of Company’s ALS Treatment During “Right-to-Try” Bill Signing – PR Newswire” and the last “BrainStorm granted Japanese Patent for Nurown – Seeking Alpha” with publication date: July 05, 2018.